AI Bio Expert: 99% Faster Drug Discovery, BioTech’s AlphaGo Moment, Building Photoshop for Molecules

In this episode of Unsupervised Learning, Jacob interviews Joshua Meier, CEO of Chai Discovery, about the current state and future of AI in biology and drug discovery. They discuss the evolution of AI models from protein structure prediction to de novo design, the different waves of AI bio companies, and the impact of these advancements on various therapeutic modalities. Meier emphasizes the importance of data generation, the role of open-source models, and the potential for AI to revolutionize drug discovery by enabling the design of novel molecules and accelerating the development process. They also touch on the implications for the pharma industry and the milestones to watch for as the field progresses.